risperidone has been researched along with Agitation, Psychomotor in 109 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function." | 9.19 | Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. ( Eriksdotter, M; Freund-Levi, Y; Jedenius, E; Lärksäter, M; Tysen-Bäckström, AC; Wahlund, LO, 2014) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 9.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 9.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 9.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 9.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0." | 9.14 | Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. ( Mowla, A; Pani, A, 2010) |
| " Therefore, it was of interest to assess the efficacy of piracetam, a positive modulator of AMPA-sensitive glutamate receptors in autistic disorder." | 9.13 | A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. ( Akhondzadeh, S; Ghelichnia, HA; Mohammadi, M; Mohammadi, MR; Nouroozinejad, GH; Shabstari, OL; Tajdar, H, 2008) |
| "No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia." | 9.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 9.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 9.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 9.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 9.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "Risperidone treatment was associated with an early and sustained reduction in nursing staff burden as measured using the M-NCAS compared with placebo treatment for older nursing home residents with dementia." | 9.11 | The effect of risperidone on nursing burden associated with caring for patients with dementia. ( Brodaty, H; Ciesla, G; Frank, L; Kleinman, L; Rupnow, MF, 2004) |
| "95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia." | 9.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 9.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 8.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Risperidone is useful for treating aggression and agitation associated with various psychiatric disorders in patients from different age groups." | 8.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression." | 7.83 | Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1. ( Li, C; Li, J, 2016) |
| "Clinicians tend to be more cautious with dosing of risperidone to geriatric patients in the ED." | 5.46 | Risperidone in the Emergency Setting is Associated with More Hypotension in Elderly Patients. ( Castillo, EM; Hopper, A; Nordstrom, K; Porter, A; Vilke, GM; Wilson, MP, 2017) |
| "Risperidone has been reported as a well-tolerated antipsychotic in children." | 5.35 | An unreported side effect of risperidone in children: sinus arrest with long pauses causing syncope. ( Ceviz, N; Karacan, M; Olgun, H; Sepetcigil, O, 2009) |
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 5.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function." | 5.19 | Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. ( Eriksdotter, M; Freund-Levi, Y; Jedenius, E; Lärksäter, M; Tysen-Bäckström, AC; Wahlund, LO, 2014) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 5.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| " The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial." | 5.16 | The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. ( Andrews, H; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, S; Sultzer, D, 2012) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 5.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks." | 5.16 | Relapse risk after discontinuation of risperidone in Alzheimer's disease. ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2012) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 5.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| "Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0." | 5.14 | Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. ( Mowla, A; Pani, A, 2010) |
| " Therefore, it was of interest to assess the efficacy of piracetam, a positive modulator of AMPA-sensitive glutamate receptors in autistic disorder." | 5.13 | A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. ( Akhondzadeh, S; Ghelichnia, HA; Mohammadi, M; Mohammadi, MR; Nouroozinejad, GH; Shabstari, OL; Tajdar, H, 2008) |
| "The results of this post hoc analysis of affective symptoms of DBDs using data from a previously published randomized, double-blind clinical comparison of risperidone and placebo in the treatment of children with DBDs and subaverage intelligence suggest that risperidone was effective in treating the factors of explosive irritability; agitated, expansive, grandiose; and depression." | 5.12 | Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. ( Biederman, J; Faraone, SV; Mick, E; Pandina, G; Spencer, T; Wozniak, J, 2006) |
| "No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia." | 5.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 5.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 5.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 5.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 5.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "Risperidone treatment was associated with an early and sustained reduction in nursing staff burden as measured using the M-NCAS compared with placebo treatment for older nursing home residents with dementia." | 5.11 | The effect of risperidone on nursing burden associated with caring for patients with dementia. ( Brodaty, H; Ciesla, G; Frank, L; Kleinman, L; Rupnow, MF, 2004) |
| "95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia." | 5.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "This pilot study investigated effectiveness and tolerability of risperidone for the treatment of psychosis and agitation in 9 inpatients with Parkinson's disease and dementia." | 5.08 | The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. ( Bakey, AA; Kunik, ME; Molinari, VA; Orengo, CA; Workman, RH, 1997) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 5.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| "Risperidone, serotonin reuptake inhibitors as a class and dextromethorphan/quinidine demonstrated evidence of efficacy for agitation in dementia, although findings for dextromethorphan/quinidine were based on a single RCT." | 4.98 | Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. ( Bell, JS; Chaiyakunapruk, N; Hilmer, SN; Kongpakwattana, K; Sawangjit, R; Tawankanjanachot, I, 2018) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 4.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
| "Risperidone is useful for treating aggression and agitation associated with various psychiatric disorders in patients from different age groups." | 4.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| " There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo." | 4.83 | The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. ( Ballard, C; Waite, J, 2006) |
| "Advances in the assessment of the behavioral and psychological symptoms of dementia (BPSD) have been employed in large-scale clinical trials of new antipsychotic medications such as risperidone." | 4.81 | Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. ( De Deyn, PP; Wirshing, WC, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression." | 3.83 | Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1. ( Li, C; Li, J, 2016) |
| "We report a case of Sydenham's chorea with neuropsychiatric symptoms who was successfully treated with low-dose risperidone." | 3.75 | Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. ( Hori, H; Korogi, Y; Nakamura, J; Nakano, H; Shimono, M; Shiota, N; Sugita, A; Takano, K; Tomoda, Y; Umene, W; Yoshimura, R, 2009) |
| "The use of the atypical neuroleptic medication, risperidone, may be considered as part of the armamentarium available to physicians treating restlessness in severe brain injuries." | 3.72 | Risperidone treatment of motor restlessness following anoxic brain injury. ( Collins, L; Silver, BV; Zidek, KA, 2003) |
| "Antipsychotic-induced akathisia is severely distressing." | 3.01 | Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. ( Burschinski, A; Davis, JM; Leucht, S; Priller, J; Schneider-Thoma, J; Siafis, S; Wang, D; Wu, H, 2023) |
| "This was a 6-week, multicenter, randomized, open-label, parallel-group, flexible dosing study." | 2.78 | An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. ( Chan, HY; Chen, KP; Chen, YY; Cheng, JS; Lin, AS; Tsai, CJ, 2013) |
| "Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol." | 2.77 | Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "To compare oral risperidone and intramuscular (IM) haloperidol, both in combination with IM lorazepam, in the management of acute agitation and psychosis in the medical emergency department." | 2.72 | Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. ( Currier, GW; McMullan, JT; Veser, BD; Veser, FH; Zealberg, J, 2006) |
| "Antipsychotic (AP) dosing is well established in nonelderly patients with acute exacerbations of schizophrenia, but not in special populations." | 2.72 | Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. ( Baloche, E; Blin, O; Bourgin-Duchesnay, J; Corruble, E; Ferreri, F; Garay, RP; Llorca, PM; Mouaffak, F; Vandel, P; Vidailhet, P, 2021) |
| " At the end of the observation, the mean dosage was 5." | 2.71 | [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis]. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2003) |
| " Mean score improvements at 30, 60, and 120 minutes after dosing were significant at each timepoint in both groups (p <." | 2.71 | Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. ( Bossie, CA; Chou, JC; Currier, GW; Feifel, D; Gharabawi, GM; Mahmoud, RA; Turkoz, I, 2004) |
| "Risperidone treatment was well tolerated, and no clinically relevant changes in EPS." | 2.70 | Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. ( Ertl, MG; Haushofer, M; Kraxberger, E; Masching, AJ; Rainer, MK, 2001) |
| "Even though akathisia is less prevalent with SGAs than with the first-generation drugs, it remains clinically important and all clinicians should be conversant with its recognition and management." | 2.45 | Akathisia and second-generation antipsychotic drugs. ( Kumar, R; Sachdev, PS, 2009) |
| "This study suggests that oral risperidone may be a safe option for acute agitation in patients presenting to the ED with alcohol intoxication." | 1.46 | Safety of Risperidone for Acute Agitation and Alcohol Intoxication in Emergency Department Patients. ( Huynh, HE; Lee, KC; Pepa, PA; Wilson, MP, 2017) |
| "Clinicians tend to be more cautious with dosing of risperidone to geriatric patients in the ED." | 1.46 | Risperidone in the Emergency Setting is Associated with More Hypotension in Elderly Patients. ( Castillo, EM; Hopper, A; Nordstrom, K; Porter, A; Vilke, GM; Wilson, MP, 2017) |
| " Although our study suggests the prescription dosage and duration of antipsychotic treatment decreased significantly after FDA warning in 2005, the duration of treatment was still long." | 1.42 | Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. ( Chiang, HL; Hwang, TJ; Hwu, HG; Lin, YT; Shan, JC; Sheu, YH, 2015) |
| "Serotonin syndrome is an iatrogenic disorder that results from serotonergic overactivity." | 1.36 | A perfect storm in the emergency department. ( Wijdicks, EF; Yee, AH, 2010) |
| "Risperidone has been reported as a well-tolerated antipsychotic in children." | 1.35 | An unreported side effect of risperidone in children: sinus arrest with long pauses causing syncope. ( Ceviz, N; Karacan, M; Olgun, H; Sepetcigil, O, 2009) |
| " These data indicate that chronic administration of RISP and HAL impede behavioral recovery after TBI and impair performance in uninjured controls." | 1.35 | Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. ( Cheng, JP; Hoffman, AN; Kline, AE; Massucci, JL; Zafonte, RD, 2008) |
| " Most people did not have any adverse effects; 5 patients (15." | 1.34 | Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe? ( Angelini, A; Bendini, C; Neri, M; Neviani, F, 2007) |
| " During the subsequent week, rates of problem behavior typically decreased without reinstating the prior dosage of medication." | 1.34 | Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates. ( Dornbusch, K; Rapp, JT; Swanson, G, 2007) |
| "Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications." | 1.31 | Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. ( Currier, GW; Simpson, GM, 2001) |
| "Vascular dementia is a predictor of treatment response." | 1.31 | Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. ( Chang, WH; Chang, YC; Chiu, CC; Huang, MC; Lane, HY; Su, MH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (8.26) | 18.2507 |
| 2000's | 57 (52.29) | 29.6817 |
| 2010's | 41 (37.61) | 24.3611 |
| 2020's | 2 (1.83) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, H | 1 |
| Siafis, S | 1 |
| Wang, D | 1 |
| Burschinski, A | 1 |
| Schneider-Thoma, J | 1 |
| Priller, J | 1 |
| Davis, JM | 1 |
| Leucht, S | 1 |
| Eckert, EM | 1 |
| Dominick, KC | 1 |
| Pedapati, EV | 1 |
| Wink, LK | 1 |
| Shaffer, RC | 1 |
| Andrews, H | 2 |
| Choo, TH | 1 |
| Chen, C | 1 |
| Kaufmann, WE | 1 |
| Tartaglia, N | 1 |
| Berry-Kravis, EM | 1 |
| Erickson, CA | 1 |
| Mouaffak, F | 1 |
| Ferreri, F | 1 |
| Bourgin-Duchesnay, J | 1 |
| Baloche, E | 1 |
| Blin, O | 1 |
| Vandel, P | 1 |
| Garay, RP | 1 |
| Vidailhet, P | 1 |
| Corruble, E | 1 |
| Llorca, PM | 1 |
| Lavretsky, H | 2 |
| Chaumette, B | 1 |
| Masson, M | 1 |
| Barde, M | 1 |
| Gay, O | 1 |
| Gaillard, R | 1 |
| Wilson, MP | 2 |
| Nordstrom, K | 2 |
| Hopper, A | 1 |
| Porter, A | 1 |
| Castillo, EM | 1 |
| Vilke, GM | 1 |
| Pepa, PA | 1 |
| Lee, KC | 1 |
| Huynh, HE | 1 |
| Ostinelli, EG | 1 |
| Hussein, M | 1 |
| Ahmed, U | 1 |
| Rehman, FU | 1 |
| Miramontes, K | 1 |
| Adams, CE | 1 |
| Kongpakwattana, K | 1 |
| Sawangjit, R | 1 |
| Tawankanjanachot, I | 1 |
| Bell, JS | 1 |
| Hilmer, SN | 2 |
| Chaiyakunapruk, N | 1 |
| Scruth, E | 1 |
| Freund-Levi, Y | 3 |
| Jedenius, E | 2 |
| Tysen-Bäckström, AC | 2 |
| Lärksäter, M | 3 |
| Wahlund, LO | 2 |
| Eriksdotter, M | 2 |
| Chan, HY | 1 |
| Lin, AS | 1 |
| Chen, KP | 1 |
| Cheng, JS | 1 |
| Chen, YY | 1 |
| Tsai, CJ | 1 |
| Walther, S | 1 |
| Moggi, F | 1 |
| Horn, H | 1 |
| Moskvitin, K | 1 |
| Abderhalden, C | 1 |
| Maier, N | 1 |
| Strik, W | 1 |
| Müller, TJ | 1 |
| Bloniecki, V | 1 |
| Auestad, B | 1 |
| Tysen Bäckström, AC | 1 |
| Aarsland, D | 1 |
| Bogaisky, M | 1 |
| Corbett, A | 1 |
| Burns, A | 2 |
| Ballard, C | 2 |
| Phizackerley, D | 1 |
| Reifler, BV | 1 |
| Blazer, D | 1 |
| Lin, YT | 1 |
| Hwang, TJ | 1 |
| Shan, JC | 1 |
| Chiang, HL | 1 |
| Sheu, YH | 1 |
| Hwu, HG | 1 |
| Li, J | 1 |
| Li, C | 1 |
| Al-Dhaher, Z | 1 |
| Kapoor, S | 1 |
| Saito, E | 1 |
| Krakower, S | 1 |
| David, L | 1 |
| Ake, T | 1 |
| Kane, JM | 2 |
| Correll, CU | 1 |
| Carbon, M | 1 |
| Sultzer, DL | 3 |
| Davis, SM | 1 |
| Tariot, PN | 3 |
| Dagerman, KS | 2 |
| Lebowitz, BD | 1 |
| Lyketsos, CG | 2 |
| Rosenheck, RA | 2 |
| Hsiao, JK | 2 |
| Lieberman, JA | 2 |
| Schneider, LS | 2 |
| Scahill, L | 1 |
| Aman, MG | 1 |
| McCracken, JT | 1 |
| McDougle, CJ | 1 |
| Vitiello, B | 1 |
| Bharadwaj, R | 1 |
| Grover, S | 1 |
| Kline, AE | 1 |
| Hoffman, AN | 1 |
| Cheng, JP | 1 |
| Zafonte, RD | 1 |
| Massucci, JL | 1 |
| Kumar, R | 1 |
| Sachdev, PS | 1 |
| Pasini, A | 1 |
| D'Agati, E | 1 |
| Casarelli, L | 1 |
| Curatolo, P | 1 |
| Landreville, P | 1 |
| Leblanc, V | 1 |
| Olgun, H | 1 |
| Sepetcigil, O | 1 |
| Karacan, M | 1 |
| Ceviz, N | 1 |
| Yee, AH | 1 |
| Wijdicks, EF | 1 |
| Mowla, A | 1 |
| Pani, A | 1 |
| Hsu, WY | 1 |
| Huang, SS | 1 |
| Lee, BS | 1 |
| Chiu, NY | 1 |
| Lim, HK | 1 |
| Kim, JJ | 1 |
| Pae, CU | 1 |
| Lee, CU | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Andoh, H | 1 |
| Kato, K | 1 |
| Sato, R | 1 |
| Akama, F | 1 |
| Sakaguchi, T | 1 |
| Matsumoto, H | 1 |
| Celikyurt, IK | 1 |
| Kayir, H | 1 |
| Ulak, G | 1 |
| Erden, FB | 1 |
| Ulusoy, GK | 1 |
| Uzbay, TI | 1 |
| Seitz, DP | 1 |
| Adunuri, N | 1 |
| Gill, SS | 1 |
| Gruneir, A | 1 |
| Herrmann, N | 2 |
| Rochon, P | 1 |
| Devanand, DP | 3 |
| Mintzer, J | 2 |
| Schultz, S | 1 |
| Sultzer, D | 2 |
| de la Pena, D | 2 |
| Gupta, S | 2 |
| Colon, S | 2 |
| Schimming, C | 2 |
| Pelton, GH | 2 |
| Levin, B | 2 |
| Fang, M | 1 |
| Chen, H | 1 |
| Li, LH | 1 |
| Wu, R | 1 |
| Li, Y | 1 |
| Liu, L | 1 |
| Ye, M | 1 |
| Huang, J | 1 |
| Zhu, S | 1 |
| Wang, G | 1 |
| Zhang, Q | 1 |
| Zheng, H | 1 |
| Zhang, L | 1 |
| Wang, B | 1 |
| Zhou, J | 1 |
| Zhao, JP | 1 |
| Salinas Botrán, A | 1 |
| Urgelés Puértolas, D | 1 |
| Peregrin Abad, E | 1 |
| Kishi, Y | 1 |
| Kato, M | 1 |
| Okuyama, T | 1 |
| Thurber, S | 1 |
| Seemüller, F | 1 |
| Schennach, R | 1 |
| Mayr, A | 1 |
| Musil, R | 1 |
| Jäger, M | 1 |
| Maier, W | 1 |
| Klingenberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 1 |
| Schmitt, A | 2 |
| Schlösser, R | 1 |
| Schneider, F | 1 |
| Ohmann, C | 1 |
| Lewitzka, U | 1 |
| Gaebel, W | 1 |
| Möller, HJ | 1 |
| Riedel, M | 1 |
| Schultz, SK | 2 |
| Andrews, HF | 1 |
| Förstl, H | 1 |
| Ismail, Z | 1 |
| Emeremni, CA | 1 |
| Houck, PR | 2 |
| Mazumdar, S | 2 |
| Rosen, J | 2 |
| Rajji, TK | 1 |
| Pollock, BG | 3 |
| Mulsant, BH | 2 |
| Gnjidic, D | 1 |
| Power, GA | 1 |
| Ling, SM | 1 |
| Bonner, AF | 1 |
| McMullen, TL | 1 |
| Tsai, C | 1 |
| Puzantian, T | 1 |
| Silver, BV | 1 |
| Collins, L | 1 |
| Zidek, KA | 1 |
| Brodaty, H | 8 |
| Ames, D | 2 |
| Snowdon, J | 2 |
| Woodward, M | 1 |
| Kirwan, J | 1 |
| Clarnette, R | 1 |
| Lee, E | 1 |
| Lyons, B | 2 |
| Grossman, F | 1 |
| Pajonk, FG | 1 |
| Schreiner, A | 1 |
| Peters, S | 1 |
| Rettig, K | 1 |
| Degner, D | 1 |
| Rüther, E | 1 |
| Currier, GW | 4 |
| Chou, JC | 1 |
| Feifel, D | 2 |
| Bossie, CA | 1 |
| Turkoz, I | 1 |
| Mahmoud, RA | 1 |
| Gharabawi, GM | 1 |
| Liu, CY | 1 |
| Juang, YY | 1 |
| Liang, HY | 1 |
| Lin, NC | 1 |
| Yeh, EK | 1 |
| Frank, L | 2 |
| Kleinman, L | 2 |
| Ciesla, G | 2 |
| Rupnow, MF | 1 |
| Heveling, T | 1 |
| Emrich, HM | 1 |
| Dietrich, DE | 1 |
| Rabinowitz, J | 3 |
| Katz, IR | 3 |
| De Deyn, PP | 6 |
| Greenspan, A | 3 |
| Davidson, M | 2 |
| Rupnow, M | 1 |
| Yoshimura, R | 3 |
| Nakamura, J | 3 |
| Shinkai, K | 2 |
| Goto, M | 1 |
| Yamada, Y | 1 |
| Kaji, K | 1 |
| Kakihara, S | 1 |
| Ueda, N | 2 |
| Kohara, K | 1 |
| Ninomiya, H | 1 |
| Egami, H | 1 |
| Maeda, H | 1 |
| Deberdt, WG | 1 |
| Dysken, MW | 1 |
| Rappaport, SA | 1 |
| Feldman, PD | 1 |
| Young, CA | 1 |
| Hay, DP | 1 |
| Lehman, DL | 1 |
| Dossenbach, M | 1 |
| Degenhardt, EK | 1 |
| Breier, A | 1 |
| Asghar Ali, AA | 1 |
| Espinoza, R | 1 |
| Kavirajan, H | 1 |
| Read, S | 1 |
| Kurz, A | 1 |
| Schwalen S, S | 1 |
| Katz, I | 2 |
| Cohen-Mansfield, J | 1 |
| Howland, RH | 1 |
| Buitelaar, J | 1 |
| Waite, J | 1 |
| Veser, FH | 1 |
| Veser, BD | 1 |
| McMullan, JT | 1 |
| Zealberg, J | 1 |
| Day, S | 1 |
| Suh, GH | 1 |
| Greenspan, AJ | 1 |
| Choi, SK | 1 |
| Biederman, J | 1 |
| Mick, E | 1 |
| Faraone, SV | 1 |
| Wozniak, J | 1 |
| Spencer, T | 1 |
| Pandina, G | 1 |
| Yumru, M | 1 |
| Eren Ozen, M | 1 |
| Savas, HA | 1 |
| Selek, S | 1 |
| Angelini, A | 1 |
| Bendini, C | 1 |
| Neviani, F | 1 |
| Neri, M | 1 |
| Sabuncuoglu, O | 1 |
| Holmes, C | 1 |
| Wilkinson, D | 1 |
| Dean, C | 1 |
| Clare, C | 1 |
| El-Okl, M | 1 |
| Hensford, C | 1 |
| Moghul, S | 1 |
| Daiello, LA | 1 |
| Blakesley, RE | 1 |
| Huber, KA | 1 |
| Villari, V | 1 |
| Rocca, P | 1 |
| Fonzo, V | 1 |
| Montemagni, C | 1 |
| Pandullo, P | 1 |
| Bogetto, F | 1 |
| Akhondzadeh, S | 1 |
| Tajdar, H | 1 |
| Mohammadi, MR | 1 |
| Mohammadi, M | 1 |
| Nouroozinejad, GH | 1 |
| Shabstari, OL | 1 |
| Ghelichnia, HA | 1 |
| Rapp, JT | 1 |
| Swanson, G | 1 |
| Dornbusch, K | 1 |
| Allen, MH | 1 |
| Umene, W | 1 |
| Hori, H | 1 |
| Nakano, H | 1 |
| Sugita, A | 1 |
| Shimono, M | 1 |
| Takano, K | 1 |
| Shiota, N | 1 |
| Tomoda, Y | 1 |
| Korogi, Y | 1 |
| Bratti, IM | 1 |
| Marder, SR | 1 |
| Raheja, RK | 1 |
| Bharwani, I | 1 |
| Penetrante, AE | 1 |
| Khan, BU | 1 |
| Workman, RH | 1 |
| Orengo, CA | 1 |
| Bakey, AA | 1 |
| Molinari, VA | 1 |
| Kunik, ME | 1 |
| Rivard, MF | 1 |
| Flynn, M | 1 |
| Ward, C | 1 |
| Rabheru, K | 1 |
| Campbell, B | 1 |
| Lodge, P | 1 |
| Tanner, M | 1 |
| McKeogh, MM | 1 |
| Meares, S | 1 |
| Draper, B | 1 |
| Buckley, PF | 1 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Baik, J | 1 |
| Koo, MS | 1 |
| Negrón, AE | 1 |
| Reichman, WE | 1 |
| Simpson, GM | 1 |
| Wirshing, WC | 1 |
| Tune, LE | 1 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Marinho, V | 1 |
| Rozenthal, M | 1 |
| Souza, FC | 1 |
| Bacaltchuk, J | 1 |
| Stoppe, A | 1 |
| Ferreira, RC | 1 |
| Bottino, C | 1 |
| Scalco, M | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Jeste, DV | 1 |
| Olin, JT | 1 |
| Rabins, PV | 1 |
| Small, GW | 1 |
| Lebowitz, B | 1 |
| Rainer, MK | 1 |
| Masching, AJ | 1 |
| Ertl, MG | 1 |
| Kraxberger, E | 1 |
| Haushofer, M | 1 |
| Lane, HY | 1 |
| Chang, YC | 1 |
| Su, MH | 1 |
| Chiu, CC | 1 |
| Huang, MC | 1 |
| Chang, WH | 1 |
| Stalman, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward[NCT00418873] | Phase 4 | 39 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Study was stopped due to difficulty in patient enrollment) | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Antipsychotic Discontinuation in Alzheimer's Disease[NCT00417482] | Phase 4 | 180 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial[NCT00249158] | Phase 3 | 344 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients[NCT01119638] | Phase 4 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
The Abnormal Involuntary Movement Scale (AIMS) assesses signs of tardive dyskinesia, a movement disorder that can occur with prolonged use of antipsychotic medication. The AIMS score ranges from 0 to 35, with higher scores indicating more severe symptoms. For each subject, the change in AIMS score between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in AIMS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Risperidone | 0.24 |
Extrapyramidal signs, also known as Parkinsonian signs, refer to signs of tremor, rigidity, and bradykinesia (slowed movement) that are seen in Parkinson's disease. Assessment of extrapyramidal signs (EPS) were made with the use of the Simpson-Angus scale (which ranges from 1-40) with higher scores indicating more extrapyramidal signs. For each subject, the change in EPS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in EPS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.20 |
| Risperidone | 0.34 |
The MMSE assesses cognition. Scores range from 0-30, with higher scores indicating better cognition. For each subject, the change in MMSE between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in MMSE over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.13 |
| Risperidone | -0.77 |
Physical Self-Maintenance Scale, which ranges from 1 to 30, with higher scores indicating WORSE functioning. For each subject, the change in PSMS between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in PSMS (worse functioning) over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.80 |
"A relapse occurred in Phase B (post-randomization) if both of the following criteria were met:~Increase in the Neuropsychiatric Inventory (NPI) core score of 30% or more OR a 5-point increase from the baseline NPI score at the end of Phase A~A score of 6 (much worse) or 7 (very much worse) on the Clinical Global Impression-Change (CGI-C) at any visit." (NCT00417482)
Timeframe: 0-16 weeks in Phase B (16-32 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Phase B Arm 1: Risperidone-Risperidone | 15 |
| Phase B Arm 2: Risperidone -Placebo | 8 |
| Phase B Arm 3: Placebo-Placebo | 24 |
Same definition and criteria as the primary outcome (NCT00417482)
Timeframe: 16-32 weeks in Phase B (32-48 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Arm 1: Risperidone - Risperidone | 2 |
| Arm 2: Risperidone - Placebo | 13 |
The Treatment Emergent Symptom Scale (TESS) assesses 26 somatic symptoms. Total scores range from 0-26, with a score of 0 or 1 for each item. Higher scores indicate more somatic symptoms. For each subject, the change in TESS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in TESS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.21 |
For each subject, the change in weight in pounds between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in weight over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 0.32 |
| Risperidone | 0.73 |
18 reviews available for risperidone and Agitation, Psychomotor
| Article | Year |
|---|---|
Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis.
Topics: Adult; Aged; Antipsychotic Agents; Humans; Psychomotor Agitation; Quetiapine Fumarate; Risperidone; | 2023 |
Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients.
Topics: Aged; Antipsychotic Agents; Humans; Psychomotor Agitation; Psychotic Disorders; Risperidone; Schizop | 2021 |
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho | 2018 |
Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Dementia; Dextromethorphan; Drug Combinations; Humans; Network Meta-Analysis; | 2018 |
Risperidone for Psychosis-Induced Aggression or Agitation.
Topics: Aggression; Antipsychotic Agents; Humans; Psychomotor Agitation; Psychotic Disorders; Risperidone | 2019 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum | 2009 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascular; Double-Bl | 2005 |
Risperidone in the management of agitation and aggression associated with psychiatric disorders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Humans; Menta | 2006 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepin | 2006 |
Managing the acutely agitated and psychotic patient.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanza | 2007 |
Chronic restlessness with antipsychotics.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Chro | 2007 |
Treatment strategies for agitation and psychosis in dementia.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Clozapine; | 1996 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Atypical antipsychotic medications in the psychiatric emergency service.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedul | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Con | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
37 trials available for risperidone and Agitation, Psychomotor
| Article | Year |
|---|---|
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantam | 2014 |
An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiepins; Female; Hospitalization; Humans; Hyperp | 2013 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; | 2014 |
Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Fema | 2014 |
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Topics: Activities of Daily Living; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepin | 2008 |
Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
Topics: Aged; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Behavioral Symptoms; Caregivers; Dou | 2010 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol | 2010 |
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Ha | 2010 |
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
Topics: Alzheimer Disease; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Humans; Psychomoto | 2012 |
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagn | 2012 |
Treatment of delirium with risperidone in cancer patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Hallucinations; Humans; Male; Middl | 2012 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Topics: Aged, 80 and over; Citalopram; Dementia; Double-Blind Method; Female; Humans; Male; Psychiatric Stat | 2013 |
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascula | 2003 |
[Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Female; Humans; Male; Prospective Studies; P | 2003 |
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Cluster Analysis | 2004 |
The effect of risperidone on nursing burden associated with caring for patients with dementia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Attitude | 2004 |
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Hum | 2004 |
Psychometric performance of an assessment scale for strain in nursing care: the M-NCAS.
Topics: Aged; Aggression; Alzheimer Disease; Australia; Dementia, Vascular; Double-Blind Method; Female; Hum | 2004 |
An open study of risperidone liquid in the acute phase of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 2005 |
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2005 |
Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Delusions; Dementia; Female; Humans; | 2005 |
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Meth | 2006 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Doub | 2006 |
Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.
Topics: Affective Symptoms; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Depre | 2006 |
Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Age | 2007 |
Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Topics: Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Dose-Response | 2007 |
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Topics: Aged, 80 and over; Antipsychotic Agents; Citalopram; Dementia; Double-Blind Method; Female; Hospital | 2007 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Diagnostic and Statistical Manual | 2008 |
The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Dementia; Female; Humans; Male; Parkinson Disease; Pilot Projects; Psych | 1997 |
A structured trial of risperidone for the treatment of agitation in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Basal Gangli | 1998 |
Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Topics: Aged; Aged, 80 and over; Aggression; Antipsychotic Agents; Behavioral Symptoms; Delusions; Dementia; | 1998 |
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
Topics: Administration, Oral; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementi | 2001 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Caregivers | 2001 |
54 other studies available for risperidone and Agitation, Psychomotor
| Article | Year |
|---|---|
Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents; Antipsychotic Agents; Child; Comorbidity; Cros | 2019 |
Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
Topics: Alzheimer Disease; Antipsychotic Agents; Hallucinations; Humans; Psychomotor Agitation; Psychotic Di | 2017 |
[Switching from antipsychotics to aripiprazole and risk of agitation].
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Psychomotor Agitation; Ris | 2018 |
Risperidone in the Emergency Setting is Associated with More Hypotension in Elderly Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Emergency Service | 2017 |
Safety of Risperidone for Acute Agitation and Alcohol Intoxication in Emergency Department Patients.
Topics: Adult; Alcoholic Intoxication; Antidepressive Agents, Second-Generation; Benzodiazepines; Blood Pres | 2017 |
Response to Bogaiksy's letter to the editor.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Irritable Mo | 2014 |
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Irritable Mo | 2014 |
Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Drug Substitution; Humans; Interpersonal Relations; Long | 2014 |
Licensed indication for risperidone in dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Humans; Psychomotor Agitation; Risperidone | 2014 |
An unsubstantiated conclusion.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Irritable Mo | 2015 |
Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Male; Middle Aged; Outpatie | 2015 |
Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Drug Combinations; Drug Therapy, Combination | 2016 |
Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
Topics: Adolescent; Aripiprazole; Arousal; Benzodiazepines; Child; Cohort Studies; Female; Humans; Male; Ola | 2016 |
Beware of over-interpreting negative trials.
Topics: Adult; Antipsychotic Agents; Awareness; Clinical Trials as Topic; Humans; Intellectual Disability; P | 2008 |
Parkinsonism and akathisia with quetiapine: three case reports.
Topics: Adolescent; Antipsychotic Agents; Dibenzothiazepines; Female; Hallucinations; Humans; Parkinsonian D | 2008 |
Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury.
Topics: Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; H | 2008 |
Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.
Topics: Abnormalities, Multiple; Adolescent; Aggression; Animals; Antipsychotic Agents; Chromosome Deletion; | 2010 |
Older adult's acceptability ratings of treatments for verbal agitation in persons with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Aging; Behavior Therapy; Dementia; Female; Humans; Male; Neurop | 2010 |
An unreported side effect of risperidone in children: sinus arrest with long pauses causing syncope.
Topics: Antipsychotic Agents; Child; Diagnosis, Differential; Dose-Response Relationship, Drug; Electrocardi | 2009 |
A washout period needed before switching from a neuroleptic to an amphetamine.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child | 2009 |
A perfect storm in the emergency department.
Topics: Aged; Alzheimer Disease; Citalopram; Drug Therapy, Combination; Female; Humans; Iatrogenic Disease; | 2010 |
Case of delirium complicated with pneumonia that improved with blonanserin administration.
Topics: Aged; Antipsychotic Agents; Delirium; Humans; Male; Piperazines; Piperidines; Pneumonia; Psychiatric | 2010 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Dep | 2011 |
[Postpartum psychosis associated with cabergoline].
Topics: Adult; Antipsychotic Agents; Cabergoline; Cesarean Section; Dopamine Agonists; Ergolines; Female; Ha | 2013 |
[Longterm treatment with Risperidone in Alzheimer's disease? No justification for more "drug deaths" in nursing homes!].
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Liquid risperidone in the treatment of psychotic agitation.
Topics: Administration, Oral; Antipsychotic Agents; Biological Availability; Clinical Trials as Topic; Human | 2002 |
Risperidone treatment of motor restlessness following anoxic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Drug Therapy, Combination; Humans; Hypoxia, | 2003 |
Efficacy of risperidone in treating the hyperactive symptoms of delirium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Fe | 2004 |
Treatment of a rare psychopathological phenomenon: tactile hallucinations and the delusional other.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Chronic Disease; Delusions; Drug Therapy | 2004 |
The effect of risperidone on nursing burden associated with caring for patients with dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Psychomotor Agitation; Risperidone; Workload | 2005 |
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studie | 2005 |
Atypical antipsychotics: special formulations for acute agitation.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Ag | 2005 |
Duration of risperidone treatment for BPSD.
Topics: Aged; Aggression; Antipsychotic Agents; Dementia; Drug Administration Schedule; Female; Humans; Male | 2006 |
Long-acting injectable risperidone for control of agitation in dementia.
Topics: Aged; Alzheimer Disease; Delayed-Action Preparations; Female; Humans; Patient Compliance; Psychiatri | 2006 |
Atypical antipsychotic agents ineffective for AD.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Ps | 2007 |
Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?
Topics: Activities of Daily Living; Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Female; Follow-Up | 2007 |
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Interactions; Female; Homovanillic Acid; Humans; | 2007 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Dementia; Diben | 2007 |
Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Female; Human | 2007 |
Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea.
Topics: Adolescent; Antipsychotic Agents; Anxiety; Basal Ganglia; Brain-Derived Neurotrophic Factor; Catecho | 2009 |
Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation.
Topics: Aged; Antipsychotic Agents; Clonazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1995 |
Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
Topics: Adult; Aggression; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Drug Adminis | 1997 |
Risperidone in the management of agitation in HIV dementia.
Topics: Adult; AIDS Dementia Complex; Antipsychotic Agents; Fatal Outcome; Humans; Male; Psychomotor Agitati | 1998 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; H | 1999 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dys | 2000 |
Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cognition; Female; Humans; | 2000 |
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen | 2001 |
Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascula | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Hyperkinesis; Psychomotor Agitation; Risperidone; Schizop | 2002 |